HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis

HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis

Abstract Objective The study analyzed the relationship between serum levels of HMGB1 and biochemical indices related to atherosclerosis, clarifying the diagnostic value of HMGB1 in cases of myeloproliferative neoplasm (MPN) accompanied by atherosclerosis (AS). Methods The bone marrow samples and ser...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lunbi Wu, Dongxue Han, Xiaodong Zhang, Shixu Zhang, Yicong Wang, Wenxue Han, Bowen Jiang, Huailei Chen, Libo Jiang
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Series:	European Journal of Medical Research
Subjects:	Myeloproliferative neoplasm Atherosclerosis HMGB1 Biomarker
Online Access:	https://doi.org/10.1186/s40001-025-02655-8
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Paola Guglielmelli, et al.
Published: (2010-05-01)

Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
by: O. Yu. Vinogradova, et al.
Published: (2025-05-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria
by: Mohamed A. Yassin, et al.
Published: (2020-07-01)

Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm
by: Hyundong Yoon, et al.
Published: (2024-09-01)

Identification of Novel Risk Variants of Inflammatory Factors Related to Myeloproliferative Neoplasm: A Bidirectional Mendelian Randomization Study
by: Yang Li, et al.
Published: (2024-01-01)

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms
by: Xiaodong Guo, et al.
Published: (2025-08-01)

USP5 inhibition via bone marrow-targeted engineered exosomes for myeloproliferative neoplasms therapy
by: Wenjun Wang, et al.
Published: (2025-07-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)

A Study on the Role of Thrombophilic Genetic Disorders as a Risk Factor for Thrombotic Complications in Patients with Myeloproliferative Disorders
by: Doroteya Todorieva-Todorova, et al.
Published: (2019-08-01)

A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence
by: Amna Bamaqa, et al.
Published: (2025-06-01)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
by: M B Agarwal, et al.
Published: (2015-01-01)

Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation
by: Roopa Dixith, et al.
Published: (2019-01-01)

DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications
by: Paola Barone, et al.
Published: (2025-03-01)

Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults
by: Linda Resar, et al.
Published: (2025-05-01)

Biology of Myeloproliferative Malignancies
by: AL Melikyan, et al.
Published: (2016-07-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01)

Association between JAK2V617F Mutation and Mean Platelet Volume among Myeloproliferative Neoplasm Patients
by: Mushtaq M. Khazeem, et al.
Published: (2025-04-01)

Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
by: Mohan B Agarwal, et al.
Published: (2018-01-01)

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
by: Joshua W. Bliss, et al.
Published: (2024-12-01)

Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome—insights from a UK center
by: Giulia Simini, et al.
Published: (2025-07-01)

Association of Pruritus With Comorbidities and Survival in Myeloproliferative Neoplasms: A Systematic Review of the Literature
by: J. Saucereau, et al.
Published: (2025-06-01)

Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan
by: Munazza Rashid, et al.
Published: (2025-08-01)

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
by: Emmanouil Spanoudakis, et al.
Published: (2018-10-01)

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms
by: Guangshuai Teng, et al.
Published: (2025-07-01)

Prevalence and clinical significance of sarcopenia in patients with chronic myeloproliferative neoplasms: epidemiology, diagnosis, and intervention strategies
by: Adelina G. Garifullina, et al.
Published: (2025-01-01)

Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990-2021: an analysis from the global burden of disease study 2021
by: Xinyue Gou, et al.
Published: (2025-03-01)

Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression
by: İldeniz USLU-BIÇAK, et al.
Published: (2025-05-01)

To the problem of thrombus-hemorrhagic complications in chronic myeloproliferative neoplasias. Complicated diagnosis. Clinical case conference
by: Nikolayenko-Kamyshova T.P.
Published: (2015-09-01)

The Association Between Serum HMGB2 Levels and Abdominal Aortic Aneurysm in Males: Insights Into the HMGB2–TREM Pathway
by: Liting Pan, et al.
Published: (2025-07-01)

Co-occurrence of unclassified myeloproliferative neoplasm and giant cell arteritis in a patient treated with allogeneic hematopoietic stem cell transplantation: a case report and literature review
by: Aleksandra Bogucka-Fedorczuk, et al.
Published: (2021-04-01)

Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm—A single-center study from North India
by: Khaliqur Rahman, et al.
Published: (2024-12-01)

Case Report: A novel t(15;17)(q24;q11.2) translocation involving NF1::SCAMP5 fusion in a patient with myeloproliferative neoplasms
by: Yuying Chang, et al.
Published: (2025-07-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
by: Fadul A, et al.
Published: (2024-12-01)

Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver
by: Alessandro Malara, et al.
Published: (2018-11-01)

To the problem of thrombus-hemorrhagic complications in chronic myeloproliferative neoplasias. Complicated diagnosis. Clinical case conference.
by: T. P. Nikolayenko-Kamyshova
Published: (2015-09-01)

Role of HMGB1 on the onset of preeclampsia
by: Mehmet Yılmaz, et al.
Published: (2025-05-01)

CalR and MPL Driver Mutations and Their Role in the Diagnosis and Clinical Course of JAK2-Unmutated Chronic Myeloproliferative Neoplasm: Results from a Pilot Single-Center Study
by: Tarık Onur Tiryaki, et al.
Published: (2025-05-01)

Serum HMGB1 as a diagnostic biomarker and mediator of childhood trauma in adolescent depression
by: Jingyue Xiang, et al.
Published: (2025-06-01)

The performance of the alarmin HMGB1 in pediatric diseases: From lab to clinic
by: Bo Li, et al.
Published: (2021-03-01)